Life Sciences & Biotechnology
Title : | Next-Generation Sequencing based Identification of Novel Biomarkers and Potential Druggable Targets in Uterine Cancer and its Subtypes |
Area of research : | Life Sciences & Biotechnology |
Principal Investigator : | Dr. Taj Mohammad, All India Institute Of Medical Sciences (AIIMS), New Delhi |
Timeline Start Year : | 2022 |
Timeline End Year : | 2024 |
Contact info : | taj144796@st.jmi.ac.in |
Details
Executive Summary : | Cancer is among the leading causes of death worldwide. It is caused due to genetic alterations, uncontrolled gene regulation, and the expression of signaling molecules. Cancer shows a diverse mutational landscape and differential gene expression patterns in different populations and cancer subtypes. One of the most extremely aggressive cancers in females is uterine cancer, affecting the reproductive system, and is most often diagnosed at age of over 55. Although the data regarding the factual incidences of uterine cancer in India is limited, it is growing day by day. An in-depth analysis of the genomic profile of uterine cancer would allow us to discover novel biomarkers, potential drug targets, and an understanding of genomic heterogeneity among uterine cancer subtypes. The next-generation sequencing (NGS) analytics has revolutionized biological and clinical research in modern science, especially in oncology. NGS is now being incorporated into standard clinical practice. Practices for the NGS analytics and physiological conditions are being combined, allowing the oncologist to act further effortlessly on genomic evidence in patient care. This project aims to explore the genomic profiles of patients with uterine cancer in the context of differential gene expression, somatic mutations, single nucleotide polymorphisms (SNPs), copy number variations (CNVs), splice variants, and survival. It will help identify druggable targets, novel biomarkers, and driver mutations associated with the progression of uterine cancer. We will utilize state-of-the-art bioinformatics approaches involving NGS analytics and structural biology to perform genomic and proteomic profiling of uterine cancer samples. We expect some novel biomarkers and potential druggable targets to be discovered for the early detection and diagnosis of cancer. This will help in personalized medical treatments and selecting suitable model organisms to better understand cancer progression and subsequent drug development. This project is also aimed to describe differences in genomic prognosis across molecularly-defined subtypes of uterine cancer and the relationship between genomic expression patterns and cancer progression. This work could ultimately guide research and clinical practice for selecting cancer treatments and predicting prognosis. |
Organizations involved